Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:CARMNYSE:NKGNNASDAQ:OBSV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$3.08-4.6%$6.71$2.81▼$485.37$2.33M5.75606,297 shs303,914 shsCARMCarisma Therapeutics$0.40-1.4%$0.29$0.14▼$1.70$16.74M1.633.75 million shs851,846 shsNKGNNKGen Biotech$0.24+7.2%$0.25$0.10▼$1.37$10.80M1.21.58 million shs71,585 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs2,500 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-26.14%-34.47%-86.25%-99.98%CARMCarisma Therapeutics0.00%-9.18%+100.60%+21.39%-67.16%NKGNNKGen Biotech0.00%-3.92%-17.17%+47.09%-81.52%OBSVObsEva0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.7545 of 5 stars3.53.00.00.03.00.01.3CARMCarisma Therapeutics2.3638 of 5 stars3.22.00.00.03.11.70.6NKGNNKGen Biotech0.3834 of 5 stars0.03.00.00.00.62.50.0OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.007,111,588.31% UpsideCARMCarisma Therapeutics 2.43Hold$1.93380.53% UpsideNKGNNKGen Biotech 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, NKGN, CARM, and OBSV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025CARMCarisma TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $1.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.75N/AN/A$65.21 per share0.05CARMCarisma Therapeutics$19.63M0.85N/AN/A($0.67) per share-0.60NKGNNKGen Biotech$80K134.96N/AN/A($2.68) per share-0.09OBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)CARMCarisma Therapeutics-$60.48M-$1.56N/AN/AN/A-254.28%-957.20%-137.38%8/6/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ALatest APVO, NKGN, CARM, and OBSV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/13/2025Q1 2025CARMCarisma Therapeutics-$0.17-$0.22-$0.05-$0.22$2.47 million$3.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACARMCarisma TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67CARMCarisma TherapeuticsN/A1.341.34NKGNNKGen BiotechN/A0.020.02OBSVObsEvaN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CARMCarisma Therapeutics44.27%NKGNNKGen Biotech76.17%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.01%CARMCarisma Therapeutics12.57%NKGNNKGen Biotech10.36%OBSVObsEva14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50760,000756,000Not OptionableCARMCarisma Therapeutics2041.79 million36.54 millionNo DataNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableAPVO, NKGN, CARM, and OBSV HeadlinesRecent News About These CompaniesObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantAugust 31, 2024 | pharmaphorum.comPObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 3, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsMarch 19, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 28, 2024 | globenewswire.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesFebruary 25, 2024 | benzinga.comObsEva SA OBSNNovember 11, 2023 | morningstar.comMObsEva SA OBSEFNovember 11, 2023 | morningstar.comMObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserverMay 10, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo FinanceMay 2, 2023 | news.google.comNObsEva Says Fabien De Ladonchamps Is New CEO - NasdaqMay 2, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswireMay 2, 2023 | news.google.comNGameto Appoints Teri Loxam as Chief Financial Officer - citybizApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Marketscreener.comApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Yahoo FinanceApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - BenzingaApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - EIN NewsApril 28, 2023 | news.google.comNGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR NewswireApril 28, 2023 | news.google.comNEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital JournalApril 26, 2023 | news.google.comNEndometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPRApril 23, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, NKGN, CARM, and OBSV Company DescriptionsAptevo Therapeutics NASDAQ:APVO$3.08 -0.15 (-4.64%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.08 +0.00 (+0.03%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Carisma Therapeutics NASDAQ:CARM$0.40 -0.01 (-1.43%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.41 +0.01 (+2.35%) As of 06/27/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.NKGen Biotech NYSE:NKGN$0.24 +0.02 (+7.23%) As of 06/27/2025 03:13 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
